Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
LC-MS
benign prostatic hyperplasia
organic acid metabolites
prostate cancer
prostatitis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
07
2022
accepted:
01
09
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Noninvasive methods for the early identify diagnosis of prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa) are current clinical challenges. The serum metabolites of 20 healthy individuals and patients with prostatitis, BPH, or PCa were identified using untargeted liquid chromatography-mass spectrometry (LC-MS). In addition, targeted LC-MS was used to verify the organic acid metabolites in the serum of a validation cohort. Organic acid metabolites had good sensitivity and specificity in differentiating prostatitis, BPH, and PCa. Three diagnostic models identified patients with PROSTATITIS: phenyllactic acid (area under the curve [AUC]=0.773), pyroglutamic acid (AUC=0.725), and pantothenic acid (AUC=0.721). Three diagnostic models identified BPH: citric acid (AUC=0.859), malic acid (AUC=0.820), and D-glucuronic acid (AUC=0.810). Four diagnostic models identified PCa: 3-hydroxy-3-methylglutaric acid (AUC=0.804), citric acid (AUC=0.918), malic acid (AUC=0.862), and phenyllactic acid (AUC=0.713). Two diagnostic models distinguished BPH from PCa: phenyllactic acid (AUC=0.769) and pyroglutamic acid (AUC=0.761). Three diagnostic models distinguished benign BPH from PROSTATITIS: citric acid (AUC=0.842), ethylmalonic acid (AUC=0.814), and hippuric acid (AUC=0.733). Six diagnostic models distinguished BPH from prostatitis: citric acid (AUC=0.926), pyroglutamic acid (AUC=0.864), phenyllactic acid (AUC=0.850), ethylmalonic acid (AUC=0.843), 3-hydroxy-3-methylglutaric acid (AUC=0.817), and hippuric acid (AUC=0.791). Three diagnostic models distinguished PCa patients with PROSTATITISA < 4.0 ng/mL from those with PSA > 4.0 ng/mL: 5-hydromethyl-2-furoic acid (AUC=0.749), ethylmalonic acid (AUC=0.750), and pyroglutamic acid (AUC=0.929). Conclusions: These results suggest that serum organic acid metabolites can be used as biomarkers to differentiate prostatitis, BPH, and PCa.
Sections du résumé
Background
Noninvasive methods for the early identify diagnosis of prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa) are current clinical challenges.
Methods
The serum metabolites of 20 healthy individuals and patients with prostatitis, BPH, or PCa were identified using untargeted liquid chromatography-mass spectrometry (LC-MS). In addition, targeted LC-MS was used to verify the organic acid metabolites in the serum of a validation cohort.
Results
Organic acid metabolites had good sensitivity and specificity in differentiating prostatitis, BPH, and PCa. Three diagnostic models identified patients with PROSTATITIS: phenyllactic acid (area under the curve [AUC]=0.773), pyroglutamic acid (AUC=0.725), and pantothenic acid (AUC=0.721). Three diagnostic models identified BPH: citric acid (AUC=0.859), malic acid (AUC=0.820), and D-glucuronic acid (AUC=0.810). Four diagnostic models identified PCa: 3-hydroxy-3-methylglutaric acid (AUC=0.804), citric acid (AUC=0.918), malic acid (AUC=0.862), and phenyllactic acid (AUC=0.713). Two diagnostic models distinguished BPH from PCa: phenyllactic acid (AUC=0.769) and pyroglutamic acid (AUC=0.761). Three diagnostic models distinguished benign BPH from PROSTATITIS: citric acid (AUC=0.842), ethylmalonic acid (AUC=0.814), and hippuric acid (AUC=0.733). Six diagnostic models distinguished BPH from prostatitis: citric acid (AUC=0.926), pyroglutamic acid (AUC=0.864), phenyllactic acid (AUC=0.850), ethylmalonic acid (AUC=0.843), 3-hydroxy-3-methylglutaric acid (AUC=0.817), and hippuric acid (AUC=0.791). Three diagnostic models distinguished PCa patients with PROSTATITISA < 4.0 ng/mL from those with PSA > 4.0 ng/mL: 5-hydromethyl-2-furoic acid (AUC=0.749), ethylmalonic acid (AUC=0.750), and pyroglutamic acid (AUC=0.929). Conclusions: These results suggest that serum organic acid metabolites can be used as biomarkers to differentiate prostatitis, BPH, and PCa.
Identifiants
pubmed: 36685547
doi: 10.3389/fimmu.2022.998447
pmc: PMC9846500
doi:
Substances chimiques
3-phenyllactic acid
156-05-8
ethylmalonic acid
432NF49DFG
hippuric acid
TE0865N2ET
malic acid
817L1N4CKP
Prostate-Specific Antigen
EC 3.4.21.77
Meglutol
CLA99KCD53
Pyrrolidonecarboxylic Acid
SZB83O1W42
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
998447Informations de copyright
Copyright © 2023 He, Han, Luo, Shen, Xie, Liao, Zou, Luo, Guo, Li, Li and Chen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Andrologia. 2015 Apr;47(3):328-32
pubmed: 24620795
Clin Nutr ESPEN. 2021 Jun;43:267-275
pubmed: 34024526
Mol Genet Genomics. 2020 Mar;295(2):327-341
pubmed: 31735985
Metabolomics. 2012;8(6):997-1011
pubmed: 23139648
Eur Urol Oncol. 2020 Aug;3(4):424-432
pubmed: 32605889
Bioanalysis. 2012 Feb;4(4):431-51
pubmed: 22394143
Biomed Pharmacother. 2017 Oct;94:1064-1076
pubmed: 28813783
BMC Cancer. 2020 Apr 22;20(1):340
pubmed: 32321456
Diagnostics (Basel). 2019 Feb 19;9(1):
pubmed: 30791464
BJU Int. 2005 Jun;95(9):1249-52
pubmed: 15892810
Metabolomics. 2018 Nov 17;14(11):152
pubmed: 30830421
Diagnostics (Basel). 2021 Mar 20;11(3):
pubmed: 33804783
Urologe A. 2020 May;59(5):544-549
pubmed: 32274543
Oncotarget. 2017 Jul 11;8(28):45190-45199
pubmed: 28423352
Nature. 2009 Feb 12;457(7231):910-4
pubmed: 19212411
J Cancer. 2020 Jan 1;11(1):177-189
pubmed: 31892984
Sci Rep. 2020 Mar 20;10(1):5157
pubmed: 32198373